Efficacy of Tocilizumab on Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

July 13, 2020

Study Completion Date

August 27, 2020

Conditions
SARS-CoV 2
Interventions
DRUG

Tocilizumab

"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"

DRUG

Placebos

"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02462

Newton-Wellesley Hospital, Newton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04356937 - Efficacy of Tocilizumab on Patients With COVID-19 | Biotech Hunter | Biotech Hunter